The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zikiryakhodzhaev A.D.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia;
Peoples’ Friendship University of Russia

Bosieva A.R.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Volchenko N.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Fedenko A.A.

Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Starkova M.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Duadze I.S.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Khugaeva F.S.

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia

Efanov V.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Usov F.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

A pathological complete response after neoadjuvant combination chemotherapy in breast cancer patients

Authors:

Zikiryakhodzhaev A.D., Bosieva A.R., Bagdasarova D.V., Volchenko N.N., Fedenko A.A., Starkova M.V., Duadze I.S., Khugaeva F.S., Efanov V.V., Usov F.N.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(1): 23‑27

DOI: 10.17116/onkolog20221101123

Read: 5325 times

Download PDF (RU)
Contact the author
Table of contents

A PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT COMBINATION CHEMOTHERAPY IN BREAST CANCER PATIENTS
A PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT COMBINATION CHEMOTHERAPY IN BREAST CANCER PATIENTS

To cite this article:

Zikiryakhodzhaev AD, Bosieva AR, Bagdasarova DV, et al. . A pathological complete response after neoadjuvant combination chemotherapy in breast cancer patients. P.A. Herzen Journal of Oncology. 2022;11(1):23‑27. (In Russ.)
https://doi.org/10.17116/onkolog20221101123

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Neoadjuvant drug therapy and onco­logical outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(1):5-12
Long-term clinical outcomes of patients with loca­lly adva­nced gastric adenocarcinoma after two indu­ction cycles of chemotherapy acco­rding to the FLOT regi­men followed by chemoradiotherapy and radi­cal surgery. P.A. Herzen Journal of Onco­logy. 2025;(2):5-12
Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant poly­chemotherapy depe­nding on Ki-67 levels. P.A. Herzen Journal of Onco­logy. 2025;(2):13-18
Hema­tological indi­cators of the systemic inflammatory response in the prognosis of lumi­nal HER2-negative breast cancer patients unde­rgoing surgery followed by adju­vant therapy. P.A. Herzen Journal of Onco­logy. 2025;(3):31-38
Hemo­stasis diso­rders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(3):39-44
The possibilities of predicting and redu­cing the risk of breast cancer in women against the background of the use of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64
The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;(2):5-10
Repeated breast reco­nstruction after previous complications. Piro­gov Russian Journal of Surgery. 2025;(6):51-57
Guidelines for asse­ssing the quality of mammographic images. Russian Journal of Preventive Medi­cine. 2025;(6):21-32
Inci­dence of regional lymph node meta­stases in patients with early prognostically unfa­vorable mole­cular biological breast cancer. Piro­gov Russian Journal of Surgery. 2025;(7):11-15
Abstract:

OBJECTIVE

To study the effect of a pathological complete response (pCR) of the tumor after neoadjuvant combination chemotherapy (NACCT) on 3- and 5-year relapse-free and overall survival rates in breast cancer (BC) patients.

Subjects and methods. The authors analyzed the 2013—2020 medical records of 200 patients with Stage II—III BC (Stage IIIB was ruled out), who underwent organ-sparing surgeries and radical mastectomies at the second stage of combination treatment after NACCT at the Department of Breast and Skin Cancer and Reconstructive and Plastic Surgery, P.A. Herzen Moscow Oncology Research Institute. The distribution of BC stages was as follows: Stage I was diagnosed in 5 (2.5%) patients; Stage II in 113 (56.5%), and Stage III in 82 (41%) (Stage IIIB was ruled out).

RESULTS

A pCR was achieved in 37 (18.5%) patients; a pathological partial response was in 163 (81.5%). The pCR was most commonly achieved in patients with invasive non-specific BC (90.5%). In the 37 patients, the pCR was achieved in patients with triple-negative BC (37.5%), Her2/neu-positive BC (30%), Her2/neu-positive luminal B BC (17.5%), and Her2/neu-negative luminal B BC (15%); pCR was most frequently observed in high-grade (G3) BC (57.5%) and in moderate-grade (G2) BC (42.5%). The 5-year relapse-free and overall survival rates were 100%. One patient was noted to have progressive disease as lung metastasis at 22 months after surgical treatment.

CONCLUSION

The investigation has established a correlation between the degree of a pathological tumor response in BC patients after NACCT and the rates of 3- and 5-year disease-free and overall survival. The predictive value of pCR is in direct proportion to the IHC-defined type of BC, which is more often detected in its aggressive morphological variants: her2/neu-positive (47.5%) and triple- negative (37.5%).

Keywords:

breast cancer
neoadjuvant combination chemotherapy
pathological complete response
relapse-free survival
overall survival

Authors:

Zikiryakhodzhaev A.D.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia;
Peoples’ Friendship University of Russia

Bosieva A.R.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Volchenko N.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Fedenko A.A.

Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Starkova M.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Duadze I.S.

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Khugaeva F.S.

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia

Efanov V.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Usov F.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Received:

27.08.2021

Accepted:

18.11.2021

Close metadata

References:

  1. Chen M, Bernstam F, Hunt K, Thames H, Oswald M, Outlaw E, Strom E, McNeese M, Kuerer H. Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson cancer center experience. J Clin Oncol. 2004;22(12):2303-2312. https://doi.org/10.1200/JCO.2004.09.062
  2. Boughey J, Peintinger F, Bernstam F, Perry A, Hunt K, Babiera G, Singletary S, Bedrosian I, Lucci A, Buzdar A, Pusztai L. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244(3):464-469.  https://doi.org/10.1097/01.sla.0000234897.38950.5c
  3. Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559-567.  https://doi.org/10.1007/s10549-018-4801-3
  4. Fayanju OM, RenY, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Hwang ES. The clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Ann Surg. 2018;268(4):591-601.  https://doi.org/10.1097/sla.0000000000002953
  5. Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann H, Fasching P, Gerber B, Eiermann W, Hilfrich J. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-1804. https://doi.org/10.1200/JCO.2011.38.8595
  6. Szentmartoni G, Tokes A, Tokes T, Somlai K, Szasz A, Torgyík L, Kulka J, Magdolna Dank. Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study. Croat Med J. 2016;57(2):131-139.  https://doi.org/10.3325/cmj.2016.57.131
  7. Poddubnaya IV, Kolyabina IV. Neoadjuvant chemotherapy for HER2-positive breast cancer. Prakticheskoe rukovodstvo. M.: MMA «MediaMedika»; 2016. (In Russ.).
  8. Kolyadina IV. The evolution of the neoadjuvant approach in primary operable breast cancer in the last decade: a fashion trend or real clinical practice? Sovremennaya onkologiy. 2017;19(1):9-16. (In Russ.).
  9. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical beneft in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.  https://doi.org/10.1016/S0140-6736(13)62422-8
  10. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA. Defnition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-1804. https://doi.org/10.1200/JCO.2011.38.8595
  11. Dowsett M, Ebbs S, Dixon J, Skene A, Grifth C, Boeddinghaus I. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: infuence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol. 2015;23(11):2477-2492. https://doi.org/10.1200/JCO.2005.07.559
  12. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342-3354. https://doi.org/10.1016/j.ejca.2012.05.023
  13. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411-2418. https://doi.org/10.1245/s10434-010-1008-1
  14. Masuda N, Lee S, Ohtani S, Im Y, Lee E, Yokota I. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147-2159. https://doi.org/10.1056/NEJMoa1612645
  15. Wunderle M, Gass P, Häberle L, Flesch V, Rauh C, Bani M, Hack C, Schrauder M, Jud S, Emons J, Erber R, Ekici A. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Res Treat. 2018;171(1):85-94.  https://doi.org/10.1007/s10549-018-4797-8
  16. Apple SK, Suthar F. How do we measure a residual tumor size in Histopathology (the gold standard) after neoadjuvant chemotherapy? Breast. 2006;15(3):370-376.  https://doi.org/10.1016/j.breast.2005.08.002
  17. Murphy C, Mukaro V, Tobler R, Asher R, Gibbs E, West L. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial. Intern Med J. 2018;48(6):699-705.  https://doi.org/10.1111/imj.13617
  18. Xuan Li, Dai D, Chen B, Tang H, Wei W. Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: A systematic review and meta-analysis. World J Surg Oncol. 2017;15(1):1-8.  https://doi.org/10.1186/s12957-017-1273-6)
  19. Bear H, Anderson S, Smith R. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2022. https://doi.org/10.1200/JCO.2005.04.1665
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.